271 related articles for article (PubMed ID: 27271022)
1. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
6. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
Ronan K; Jordan E; Leonard C; McDermott R
Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
[TBL] [Abstract][Full Text] [Related]
11. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
[TBL] [Abstract][Full Text] [Related]
14. The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.
Yuan X; Liu C; Wang K; Liu L; Liu T; Ge N; Kong F; Yang L; Björkholm M; Fan Y; Zhao S; Xu D
Oncotarget; 2016 May; 7(18):25826-35. PubMed ID: 27029078
[TBL] [Abstract][Full Text] [Related]
15. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Pal SK; Bajorin D; Dizman N; Hoffman-Censits J; Quinn DI; Petrylak DP; Galsky MD; Vaishampayan U; De Giorgi U; Gupta S; Burris HA; Soifer HS; Li G; Wang H; Dambkowski CL; Moran S; Daneshmand S; Rosenberg JE
Cancer; 2020 Jun; 126(11):2597-2606. PubMed ID: 32208524
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma.
Zengin ZB; Chehrazi-Raffle A; Salgia NJ; Muddasani R; Ali S; Meza L; Pal SK
Urol Oncol; 2022 Feb; 40(2):25-36. PubMed ID: 34840077
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis.
Rizzo A; Mollica V; Santoni M; Massari F
Clin Genitourin Cancer; 2022 Oct; 20(5):482-487. PubMed ID: 35858936
[TBL] [Abstract][Full Text] [Related]
18. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
19. ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Kikuchi A; Suzuki T; Nakazawa T; Iizuka M; Nakayama A; Ozawa T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Cancer Sci; 2017 Feb; 108(2):236-242. PubMed ID: 27885740
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]